Aurobindo Pharma Limited (AUROPHARMA.NS) stock analysis

In our weekly check, Aurobindo Pharma Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 3.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as AUROPHARMA.NS.

What our checks show for AUROPHARMA.NS

Red flags

Warning signs

Strengths

Next earnings report: 2026-11-04

Similar companies

LUPIN.NS · MANKIND.NS · CIPLA.BO · DRREDDY.NS · ZYDUSLIFE.NS · LAURUSLABS.NS

Questions

What grade does Aurobindo Pharma Limited (AUROPHARMA.NS) have?

In our weekly check, Aurobindo Pharma Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of AUROPHARMA.NS stock?

This week's biggest flags for Aurobindo Pharma Limited: Gross margin falling, Deep past fall, Low return on capital. In total 4 of 25 checks show a warning or a red flag.

What does Aurobindo Pharma Limited do?

Aurobindo Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as AUROPHARMA.NS.

When does Aurobindo Pharma Limited report earnings next?

The next earnings report is expected on 2026-11-04. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis